Home > Dermatology > EADV 2022 > A new biologic treatment for HS: secukinumab is on the doorstep

A new biologic treatment for HS: secukinumab is on the doorstep

Presented By
Prof. Alexandra Kimball, Harvard Medical School, MA, USA
Conference
EADV 2022
Trial
Phase 3, SUNSHINE; SUNRISE
The IL-17A blocker, secukinumab, achieved not only a clinical response in more than 40% of hidradenitis suppurative patients but also reduced abscesses and pain and improved quality-of-life in the 2 phase 3 trials SUNSHINE and SUNRISE. The positive results were accompanied by a consistent safety profile, demonstrating the overall high potential of secukinumab for hidradenitis suppurativa (HS) therapy. SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) recruited worldwide over 1,000 patients with HS at 219 sites. “This is only the second phase 3 programme we have ever seen in HS and the first one since 2016, so it really is a milestone,” Prof. Alexandra Kimball (Harvard Medical School, MA, USA) highlighted. The 52-week studies assessed secukinumab after a loading phase adminis...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on